{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:47:23Z","timestamp":1793296043802,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008741","name":"EULAR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008741","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ard.2026.02.024","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T03:48:29Z","timestamp":1775620109000},"page":"1055-1072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8481-6343","authenticated-orcid":false,"given":"Faidra","family":"Laskou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Konzett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e9sir\u00e9e","family":"van der Heijde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E","family":"Pope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimme","family":"Hyrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savia","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja A","family":"Stamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jette","family":"Primdahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan W","family":"Schoones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert BM","family":"Landew\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kerschbaumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study","volume":"5","author":"Mehta","year":"2019","journal-title":"RMD Open"},{"issue":"10","key":"10.1016\/j.ard.2026.02.024_bib0002","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"13","key":"10.1016\/j.ard.2026.02.024_bib0003","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0004","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.024_bib0005","unstructured":"Agency. EM. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders [cited 2026 Jan 14]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/janus-kinase-inhibitors-jaki"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.024_bib0007","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0008","doi-asserted-by":"crossref","first-page":"rkac014","DOI":"10.1093\/rap\/rkac014","article-title":"Extra-articular findings with FDG-PET\/CT in rheumatoid arthritis patients: more harm than benefit","volume":"6","author":"Ulijn","year":"2022","journal-title":"Rheumatol Adv Pract"},{"issue":"720","key":"10.1016\/j.ard.2026.02.024_bib0009","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.3399\/BJGP.2021.0595","article-title":"Persistently normal blood tests in patients taking methotrexate for RA or azathioprine for IBD: a retrospective cohort study","volume":"72","author":"Fraser","year":"2022","journal-title":"Br J Gen Pract"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0010","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.ard.2026.02.024_bib0011","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2026.02.024_bib0012","doi-asserted-by":"crossref","unstructured":"Kerschbaumer A, Konzett VL Edwards CJ, Aletaha D, van der Heijde D, Winthrop KL, et al. Efficacy of synthetic and biological DMARDs and glucocorticoids: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis. in press - accepted for publication ARDS 18\/03\/2026.","DOI":"10.1016\/j.ard.2026.03.020"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"key":"10.1016\/j.ard.2026.02.024_bib0014","unstructured":"EULAR. Standard operating procedures for task forces. [cited 2025 Nov 24]. Available from: https:\/\/www.eular.org\/sops-for-eular-post-tf-implementation-projects"},{"key":"10.1016\/j.ard.2026.02.024_bib0015","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2019"},{"key":"10.1016\/j.ard.2026.02.024_bib0016","series-title":"Evidence-based medicine: how to practice and teach EBM","author":"Sackett","year":"2005"},{"key":"10.1016\/j.ard.2026.02.024_bib0017","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2026.02.024_bib0018","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2026.02.024_bib0019","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"7","key":"10.1016\/j.ard.2026.02.024_bib0020","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1093\/rheumatology\/kead515","article-title":"Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?","volume":"63","author":"Lauper","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0021","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002636","article-title":"Antirheumatic treatment, disease activity and risk of Staphylococcus aureus bacteraemia in rheumatoid arthritis: a nationwide nested case-control study","volume":"8","author":"Dieperink","year":"2022","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44841-w","article-title":"Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care","volume":"13","author":"Riek","year":"2023","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.ard.2026.02.024_bib0023","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1093\/rheumatology\/keae132","article-title":"Rheumatoid arthritis and risk of osteoarticular infection and death following Staphylococcus aureus bacteraemia: a nationwide cohort study","volume":"63","author":"Dieperink","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2026.02.024_bib0024","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/ard-2022-223762","article-title":"Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme","volume":"82","author":"Frisell","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/rheumatology\/kead198","article-title":"Safety of the JAK and TNF inhibitors in rheumatoid arthritis: real world data from the Hong Kong Biologics Registry","volume":"63","author":"Mok","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0026","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13075-023-03111-w","article-title":"Comparative risk of infections between JAK inhibitors versus TNF inhibitors among patients with rheumatoid arthritis: a cohort study","volume":"25","author":"Choi","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0027","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/mr\/road031","article-title":"Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated with tocilizumab or other biological\/targeted synthetic disease-modifying antirheumatic drugs: evaluation of data from a Japanese claims database","volume":"34","author":"Harigai","year":"2024","journal-title":"Mod Rheumatol"},{"issue":"10","key":"10.1016\/j.ard.2026.02.024_bib0028","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1093\/rheumatology\/kead079","article-title":"Comparison of risks of cancer, infection, and MACEs associated with JAK inhibitor and TNF inhibitor treatment: a multicentre cohort study","volume":"62","author":"Uchida","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.024_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152019","article-title":"Infectious risk of add-on leflunomide or tacrolimus versus TNF inhibitors among patients with rheumatoid arthritis receiving background methotrexate: a population-based cohort study","volume":"55","author":"Shin","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ard.2026.02.024_bib0030","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/phar.2946","article-title":"Incidence of serious infections in the working-age Japanese adult population with rheumatoid arthritis treated with tumor necrosis factor-\u03b1 inhibitors and interleukin-6 inhibitors: a nationwide retrospective cohort study","volume":"44","author":"Ota","year":"2024","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ard.2026.02.024_bib0031","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.3390\/jcm11112955","article-title":"Risk of severe infection among rheumatoid arthritis patients on biological DMARDs: a population-based cohort study","volume":"11","author":"Bellan","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2026.02.024_bib0032","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3390\/jcm13103000","article-title":"Incidence rates of infections in rheumatoid arthritis patients treated with Janus kinase or interleukin-6 inhibitors: results of a retrospective, multicenter cohort study","volume":"13","author":"Yoshida","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.ard.2026.02.024_bib0033","doi-asserted-by":"crossref","first-page":"6998","DOI":"10.3390\/jcm12226998","article-title":"Association of tumor necrosis factor inhibitors with the risk of nontuberculous mycobacterial infection in patients with rheumatoid arthritis: a nationwide cohort study","volume":"12","author":"Park","year":"2023","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.ard.2026.02.024_bib0034","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1007\/s10067-024-06980-x","article-title":"Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs","volume":"43","author":"Opdam","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13075-022-02871-1","article-title":"Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study","volume":"24","author":"Jeong","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0036","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40744-024-00674-1","article-title":"Drug persistence and incidence of active tuberculosis of tumor necrosis factor alpha inhibitors versus tocilizumab as the first-line biological treatment in patients with rheumatoid arthritis: a nationwide population-based retrospective cohort analysis","volume":"11","author":"So","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0037","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003946","article-title":"Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis","volume":"10","author":"Song","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.024_bib0038","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1111\/1756-185X.14414","article-title":"Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis","volume":"25","author":"Fang","year":"2022","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003038","article-title":"COVID-19 outcomes in patients with rheumatoid arthritis with biologic or targeted synthetic DMARDs","volume":"9","author":"Tsai","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.024_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152149","article-title":"Rituximab is associated with worse COVID-19 outcomes in patients with rheumatoid arthritis: a retrospective, nationally sampled cohort study from the U.S. National COVID Cohort Collaborative (N3C)","volume":"58","author":"Singh","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.ard.2026.02.024_bib0041","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15406","article-title":"Safety outcomes of tocilizumab and tofacitinib treatment for rheumatoid arthritis: target trial emulation","volume":"27","author":"Fang","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0042","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kead163","article-title":"Cancer risk in patients with rheumatoid arthritis treated with Janus kinase inhibitors: a nationwide Danish register-based cohort study","volume":"63","author":"Westermann","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.024_bib0043","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/ard-2022-223636","article-title":"Behalf of the ARTIS group. Cancer risks with JAKi and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis or psoriatic arthritis: a national real-\u00adworld cohort study","volume":"82","author":"Huss","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0044","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002139","article-title":"Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare database","volume":"8","author":"Seror","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.024_bib0045","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2023045","article-title":"Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data","volume":"45","author":"Min","year":"2023","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.ard.2026.02.024_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1267749","article-title":"Safety of JAK and IL-6 inhibitors in patients with rheumatoid arthritis: a multicenter cohort study","volume":"14","author":"Yoshida","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ard.2026.02.024_bib0047","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1093\/rheumatology\/keab570","article-title":"Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice","volume":"61","author":"Huss","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.024_bib0048","first-page":"110","article-title":"Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study","volume":"41","author":"Lee","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0049","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002614","article-title":"Association between malignancy risk and Janus kinase inhibitors versus tumour necrosis factor inhibitors in Korean patients with rheumatoid arthritis: a nationwide population-based study","volume":"8","author":"Song","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.024_bib0050","article-title":"Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: results from a 10-year international post-marketing study","volume":"64","author":"Simon","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0051","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13075-022-02868-w","article-title":"The risk of newly diagnosed cancer in patients with rheumatoid arthritis by TNF inhibitor use: a nationwide cohort study","volume":"24","author":"Choi","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"10.1016\/j.ard.2026.02.024_bib0052","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.46336","article-title":"Use of biologic or targeted synthetic disease-modifying antirheumatic drugs and cancer risk","volume":"7","author":"Sendaydiego","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ard.2026.02.024_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152341","article-title":"Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: results from the BIOBADASER register","volume":"64","author":"Molina-Collada","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0054","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/pds.5546","article-title":"Examining the potential direct cardiovascular benefit of tumor-necrosis factor inhibitor in rheumatoid arthritis: natural and controlled direct effect analyses","volume":"32","author":"Yoshida","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0055","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003489","article-title":"Risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register","volume":"9","author":"Meissner","year":"2023","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0056","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003648","article-title":"Are JAKis more effective among elderly patients with RA, smokers and those with higher cardiovascular risk? A comparative effectiveness study of b\/tsDMARDs in Sweden","volume":"9","author":"Bower","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.024_bib0057","article-title":"Risk of dyslipidemia and major adverse cardiac events with tofacitinib versus adalimumab in rheumatoid arthritis: a real-world cohort study from 7580 patients","volume":"15","author":"Ma","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0058","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003885","volume":"10","author":"Sakai","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0059","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10067-023-06709-2","article-title":"Risk of incident cardiovascular events with disease-modifying anti-rheumatic drugs among adults with rheumatoid arthritis: a nested case-control study","volume":"43","author":"Huang","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0060","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/ard-2022-222824","article-title":"Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study","volume":"82","author":"Hoisnard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.024_bib0061","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1093\/rheumatology\/kead531","article-title":"Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population","volume":"63","author":"Popa","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.024_bib0062","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1165711","article-title":"Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study","volume":"14","author":"Song","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ard.2026.02.024_bib0063","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jacc.2022.04.039","article-title":"Cardiovascular risks of hydroxychloroquine vs methotrexate in patients with rheumatoid arthritis","volume":"80","author":"D\u2019Andrea","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0064","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/joim.13681","article-title":"Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: a multi-centre cohort study","volume":"294","author":"Tong","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.ard.2026.02.024_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152461","article-title":"Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: an analysis of postmarketing spontaneous safety reports","volume":"67","author":"Goldman","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.ard.2026.02.024_bib0066","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/annrheumdis-2021-221996","article-title":"Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: results from four Nordic countries","volume":"81","author":"Delcoigne","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.02.024_bib0067","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/acr.25005","article-title":"Hydroxychloroquine and risk of long QT syndrome in rheumatoid arthritis: a veterans cohort study with nineteen-year follow-up","volume":"75","author":"Qui\u00f1ones","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0068","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003630","article-title":"Comparative cardiovascular safety with Janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis","volume":"9","author":"Bower","year":"2023","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0069","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.024_bib0070","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ueg2.12736","article-title":"Gastrointestinal perforations associated with JAK inhibitors: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Goldman","year":"2025","journal-title":"United European Gastroenterol J"},{"issue":"9","key":"10.1016\/j.ard.2026.02.024_bib0071","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1002\/art.42862","article-title":"Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to Janus kinase inhibitors versus adalimumab: a nationwide cohort study","volume":"76","author":"Hoisnard","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0072","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002924","article-title":"Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers","volume":"9","author":"Delcoigne","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.ard.2026.02.024_bib0073","doi-asserted-by":"crossref","first-page":"rkad053","DOI":"10.1093\/rap\/rkad053","article-title":"Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)","volume":"7","author":"Mielnik","year":"2023","journal-title":"Rheumatol Adv Pract"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0074","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/kead232","article-title":"The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis","volume":"63","author":"Bredemeier","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.024_bib0075","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/rheumatology\/keae081","article-title":"Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study","volume":"64","author":"Jinno","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.ard.2026.02.024_bib0076","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","article-title":"Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u2018JAK-pot\u2019 collaboration","volume":"81","author":"Lauper","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0077","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003160","article-title":"Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study","volume":"9","author":"Ebina","year":"2023","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0078","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-072300","article-title":"Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA","volume":"14","author":"Gilbert","year":"2024","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0079","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10238-024-01360-w","article-title":"Safety of Janus kinase inhibitors compared to biological DMARDs in patients with rheumatoid arthritis and renal impairment: the ANSWER cohort study","volume":"24","author":"Nakayama","year":"2024","journal-title":"Clin Exp Med"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/rheumatology\/kead299","article-title":"IL-6 inhibitors and JAK inhibitors as favourable treatment options for patients with anaemia and rheumatoid arthritis: ANSWER cohort study","volume":"63","author":"Nakayama","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2026.02.024_bib0081","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1093\/rheumatology\/kead620","article-title":"Comparative effectiveness of biological disease-modifying antirheumatic drugs and Janus kinase inhibitor monotherapy in rheumatoid arthritis","volume":"63","author":"Onishi","year":"2024","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0082","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063198","article-title":"Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada","volume":"13","author":"Movahedi","year":"2023","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0083","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/mr\/roac025","article-title":"Effectiveness of tacrolimus concomitant with biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis","volume":"33","author":"Terabe","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.02.024_bib0084","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/14740338.2023.2172157","article-title":"First-time adverse drug reactions, survival analysis, and the share of adverse drug reactions in treatment discontinuation in real-world rheumatoid arthritis patients: a comparison of first-time treatment with adalimumab and etanercept","volume":"22","author":"Velthuis","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0085","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003045","article-title":"Disease-modifying anti-rheumatic drugs associated with different diabetes risks in patients with rheumatoid arthritis","volume":"9","author":"Su","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0086","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10067-023-06735-0","article-title":"Potential alleviation of bone mineral density loss with Janus kinase inhibitors in rheumatoid arthritis","volume":"43","author":"Chen","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2026.02.024_bib0087","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.amjmed.2022.01.017","article-title":"Biological disease-modifying antirheumatic drugs and osteoporotic fracture risk in patients with rheumatoid arthritis: a Danish cohort study","volume":"135","author":"Abtahi","year":"2022","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0088","doi-asserted-by":"crossref","DOI":"10.1111\/1756-185X.15055","article-title":"Analyzing the risk of osteoporosis and fracture in rheumatoid arthritis patients who have been treated with various biologics","volume":"27","author":"Su","year":"2024","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0089","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002445","article-title":"Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark","volume":"8","author":"Secher","year":"2022","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0090","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003366","article-title":"Glucocorticoid trajectories over 2 years in patients with rheumatoid arthritis in a real-life setting","volume":"9","author":"Delteil","year":"2023","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.ard.2026.02.024_bib0091","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/art.42928","article-title":"Association of cardiovascular outcomes with low-dose glucocorticoid prescription in patients with rheumatoid arthritis","volume":"76","author":"Coburn","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0092","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/mr\/roac103","article-title":"Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"20","key":"10.1016\/j.ard.2026.02.024_bib0093","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0094","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003317","article-title":"The MIDORA trial: a phase II, randomised, double-blind, placebo-controlled, mechanistic insight and dosage optimisation study of the efficacy and safety of dazodalibep in patients with rheumatoid arthritis","volume":"9","author":"Kivitz","year":"2023","journal-title":"RMD Open"},{"issue":"12","key":"10.1016\/j.ard.2026.02.024_bib0095","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard-2023-224482","article-title":"Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)","volume":"82","author":"Fleischmann","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ard.2026.02.024_bib0096","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/ard-2023-224449","article-title":"Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)","volume":"82","author":"Taylor","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0097","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13075-023-03038-2","article-title":"The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept: subanalysis of AVERT-2, a randomized phase IIIb study","volume":"25","author":"Emery","year":"2023","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.ard.2026.02.024_bib0098","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/S2665-9913(23)00089-9","article-title":"Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study","volume":"5","author":"Conaghan","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ard.2026.02.024_bib0099","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1136\/ard-2024-226385","article-title":"Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial","volume":"84","author":"Liu","year":"2025","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0100","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003596","article-title":"Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study","volume":"10","author":"Zubrzycka-Sienkiewicz","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0101","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(23)00237-0","volume":"6","author":"Leng","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0102","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40744-023-00544-2","article-title":"Efficacy and safety of CMAB008 compared with innovator infliximab in patients with moderate-to-severe rheumatoid arthritis receiving concomitant methotrexate: a randomized, double-blind, multi-center, phase III non-inferiority study","volume":"10","author":"Ye","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0103","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/rheumatology\/keab460","article-title":"Efficacy and safety of switching from reference adalimumab to CT-P17 (100 mg\/ml): 52-week randomized, double-blind study in rheumatoid arthritis","volume":"61","author":"Furst","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0104","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40744-021-00396-8","article-title":"Fine comparison of the efficacy and safety between GB242 and infliximab in patients with rheumatoid arthritis: a phase III study","volume":"9","author":"Liu","year":"2022","journal-title":"Rheumatol Ther"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0105","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40744-022-00519-9","article-title":"Sustained remission and outcomes with abatacept plus methotrexate following stepwise dose de-escalation in patients with early rheumatoid arthritis","volume":"10","author":"Emery","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"10","key":"10.1016\/j.ard.2026.02.024_bib0106","article-title":"A novel humanized anti-interleukin-6 antibody HZ0408b with anti-rheumatoid arthritis therapeutic potential","volume":"12","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0107","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004514","article-title":"Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47","volume":"10","author":"Smolen","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0108","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s13075-024-03375-w","volume":"26","author":"Leng","year":"2024","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0109","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2026.02.024_bib0110","first-page":"1432","article-title":"Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination","volume":"40","author":"Galloway","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0111","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"10.1016\/j.ard.2026.02.024_bib0112","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0113","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1136\/ard-2022-222543","article-title":"Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"82","author":"Curtis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0114","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11926-025-01200-0","article-title":"Treatment of persons with rheumatoid arthritis with a history of cancer","volume":"27","author":"Shasti-Nazem","year":"2025","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0115","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12874-025-02633-y","article-title":"Causal estimation of time-varying treatments in observational studies: a scoping review of methods, applications, and missing data practices","volume":"25","author":"Rop","year":"2025","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0116","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrcardio.2016.185","article-title":"Inflammatory processes in cardiovascular disease: a route to targeted therapies","volume":"14","author":"Ruparelia","year":"2017","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.024_bib0117","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kes243","article-title":"Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis","volume":"52","author":"Liao","year":"2013","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0118","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11926-017-0643-y","article-title":"Managing cardiovascular disease risk in rheumatoid arthritis: clinical updates and three strategic approaches","volume":"19","author":"Chodara","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"6","key":"10.1016\/j.ard.2026.02.024_bib0119","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","article-title":"EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome","volume":"81","author":"Drosos","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2026.02.024_bib0120","unstructured":"European Medicines Agency. EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. [cited 2022 Nov 11]. Available from: https:\/\/go.nature.com\/48tdDis"},{"issue":"4","key":"10.1016\/j.ard.2026.02.024_bib0121","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/1062860606288774","article-title":"Lafferty WE. Challenges of using medical insurance claims data for utilization analysis","volume":"21","author":"Tyree","year":"2006","journal-title":"Am J Med Qual"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0122","doi-asserted-by":"crossref","first-page":"rkae077","DOI":"10.1093\/rap\/rkae077","article-title":"The prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs: British Society for Rheumatology guideline scope","volume":"8","author":"Mercer","year":"2024","journal-title":"Rheumatol Adv Pract"},{"issue":"2","key":"10.1016\/j.ard.2026.02.024_bib0123","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpurol.2024.11.021","article-title":"Randomized controlled trials - the what, when, how and why","volume":"21","author":"Braga","year":"2025","journal-title":"J Pediatr Urol"},{"key":"10.1016\/j.ard.2026.02.024_bib0124","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ncprheum0626","article-title":"Primer: challenges in randomized and observational studies","volume":"3","author":"Landew\u00e9","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0125","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"23","key":"10.1016\/j.ard.2026.02.024_bib0126","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1056\/NEJMra1510065","article-title":"Interpreting geographic variations in results of randomized, controlled trials","volume":"375","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ard.2026.02.024_bib0127","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcin.2008.01.008","article-title":"Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations","volume":"1","author":"Hannan","year":"2008","journal-title":"JACC Cardiovasc Interv"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726001433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726001433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:15:44Z","timestamp":1780323344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726001433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":127,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003496726001433"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.024","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}